

UROLOGY

Contration of

Boston Scientific supplement • emjreviews.com

INSIDE GreenLight XPS[™] Vaporisation of the Prostate Has Proven Cost-Effective

GREENLIGHT XPS[™] VAPORISATION OF THE **PROSTATE HAS PROVEN COST-EFFECTIVE**

*Gordon Muir,¹ Neil Barber,² Simone Giona,¹ James Andrew Thomas³

1. King's College Hospital, London, UK 2. Frimley Park Hospital, London, UK 3. Princess of Wales Hospital, Bridgend, UK *Correspondence to gordon@london-urology.co.uk

Disclosure: Gordon Muir has received speaker and mentoring fees from Boston Scientific and Neotract. Neil Barber has received speaker and mentoring fees from Boston Scientific, Neotract, Olympus, and Intuitive Surgical. Simone Giona has declared no disclosures. James Andrew Thomas has received speaker and mentoring fees from Boston Scientific and Procept Biorobotic.

Support: The publication of this article was funded by Boston Scientific. The views and opinions expressed are those of the authors and not necessarily of Boston Scientific.

Received: 27.06.16 **Accepted:** 09.08.16 Citation: EMJ Urol. 2016;4(Suppl 15):2-7.

ABSTRACT

Benign prostatic hyperplasia (BPH) is common in men aged >60 years, affecting urinary and bladder function. Due to the progressive nature of the disease, many men initially treated with conservative therapies require surgical intervention for symptom relief. Less invasive techniques, such as transurethral microwave therapy, needle ablation, transurethral resection of the prostate (TURP), and laser treatment, have been developed with TURP being the standard of care for BPH in Europe in prostates <80 mL (volume).

For an increasingly ageing male population often receiving anticoagulants for cardiovascular comorbidities, TURP may not be suitable due to high risk of bleeding, requirement for bladder washouts, and blood transfusions. Owing to these requirements and potential complications associated with surgery, TURP is performed as inpatient surgery requiring a 2 to 4-day hospital stay.

In the GOLIATH study, the 180 W GreenLight XPS™ laser system demonstrated comparable efficacy with TURP at 6 and 12 months, while maintaining low rates of adverse events, retreatments, or postoperative interventions in low-risk patients. Recovery parameters significantly favoured GreenLight XPS over TURP, thus greatly supporting GreenLight XPS use for BPH treatment during short-term stay.

There is a requirement for healthcare services to minimise costs. Estimated on a day-case basis, GreenLight XPS was significantly more cost-effective than TURP with a 25% reduction in procedural cost, lower indirect costs, and lower financial burden based on efficacy and adverse-event outcomes. Therefore, GreenLight XPS represents an appropriate treatment option for day-case surgery and a treatment that can be tailored to individual patient needs.

Keywords: Benign prostatic hyperplasia (BPH), transurethral resection of the prostate (TURP), day-case surgery, GreenLight laser photoselective vaporisation, cost-effectiveness, anticoagulants.

INTRODUCTION

increase in prostate size due to the proliferation of cells. The resulting bladder outflow obstruction may cause frequent or painful urination, incontinence, a poor stream with hesitancy, straining to void, and an increased risk of urinary tract infection.


The incidence of BPH is 50-60% in men aged 60-70 years and increases to 80-90% by ages Benign prostatic hyperplasia (BPH) describes an 70-80 years.¹ Due to the progressive nature of the disease, many men initially treated with conservative therapies require surgical intervention for symptom relief. Traditionally, treatment of BPH includes watchful waiting, pharmacological approaches, and open prostatectomy. However, with the

advent of minimally invasive techniques such as compared with TURP have definitively proven the effectiveness of PVP.⁸⁻¹⁰ The GOLIATH study is transurethral microwave therapy or needle ablation, transurethral resection of the prostate (TURP), and a randomised, multicentre, non-inferiority study laser treatment, physicians have largely moved comparing 180 W GreenLight XPS and TURP.8-10 away from open prostatectomy. Comparable efficacy in terms of International Prostate Symptom Score (IPSS), maximum urinary TURP is the standard of care for BPH in Europe, flow rate, and residual urine were demonstrated at with open prostatectomy and laser enucleation 6 and 12 months.^{8,9} In terms of safety, there were reserved for patients with larger glands no significant differences in adverse events,⁸⁻¹⁰ (prostate >80 mL).² Most urologists have been and very few adverse events or retreatments were trained in TURP; however, for an increasingly reported in either arm.¹⁰ Recovery parameters also ageing male population, who to a large extent significantly favoured GreenLight XPS over TURP, receive anticoagulants to treat cardiovascular with shorter length of catheterisation and time to comorbidities, TURP may not be suitable due stable health (defined as the ability to void without to the high risk of bleeding,³ and the need for an indwelling catheter, a post-void residual urine bladder washouts and blood transfusions. Most of <100 mL) and hospitalisation (Figure 1), factors complications are associated with a long operative that greatly support shorter-term stay of patients time. Bipolar TURP may allow safer management undergoing surgery for BPH with GreenLight of patients with cardiac comorbidities and larger XPS. Comparison of erectile function revealed prostate volumes² as the potentially fatal TUR that it was similar between the treatment arms syndrome is much less likely than with monopolar at baseline and 12 months as measured by the TURP. Both methods of TURP are performed as International Index of Erectile Function,⁹ confirming inpatient surgery usually requiring a hospital stay results from previous studies; although it must of 2-4 days. be noted that these studies used the 80 W system.¹¹ The early postoperative reintervention Within any health service, there are drivers to create rate (within 30 days) was 3-times higher after efficiencies to improve patient safety and minimise TURP compared with GreenLight (9.8% versus 2.9%; cost. In light of recent economic challenges, total p=0.025).⁸ Overall, postoperative reintervention healthcare spending across the Organisation for rates were not significantly different between Economic Co-operation and Development (OECD) treatment arms.⁸


countries has fallen sharply since 2009.⁴ Therefore, alternative procedures have been developed

The significant results observed for the GreenLight in an attempt to minimise invasiveness, reduce XPS Laser Therapy System in the main trial complications, and shorten recovery times. were reflected in a UK-based subanalysis of the GOLIATH study (Figure 1).¹² When comparing GreenLight laser photoselective vaporisation of treatments, patients receiving surgery with the the prostate (PVP) has evolved over the past 16 GreenLight XPS system reported reduction in years from the 80 W photoselective vaporisation hospital stay by 1 day and significant benefits system to the current 180 W GreenLight XPS™ in terms of stable health as well as a reduction laser system.⁵ During PVP, a fibre that conducts a in the duration of catheterisation.8 Durability of high-power 532 nm wavelength laser is inserted treatment outcomes was demonstrated over into the urethra that vaporises prostatic tissue.⁶ 24 months with comparable efficacy and safety The efficacy and safety of GreenLight, as well as profiles or quality of life for GreenLight XPS practice and treatment recommendations, will be compared with TURP.¹⁰ reviewed here.


Early discharge of patients receiving treatment CLINICAL EVIDENCE AND SUITABILITY with the GreenLight XPS system has been **OF GREENLIGHT FOR** demonstrated across Europe due to lower rates of DAY-CASE SURGERY complications/morbidity seen with this technique. The GOLIATH study had specific inclusion and Currently, a limited number of patients are treated exclusion criteria, excluding patients experiencing as day cases but evidence suggests that up to 75% urinary retention or those with an enlarged of patients who require treatment for an enlarged prostate (>100 g), patients >80 years of age, or prostate could be managed on an ambulatory patients with bleeding disorders or cardiovascular care basis.⁷ Randomised studies of GreenLight comorbidities <180 days prior to consent.



King's Practice - "fast" TWOC at 2 hours for majority of patients 70% void on day of surgery, others take small catheter home.



Local reimbursement may have skewed overall data.



Some centres limited in ability to discharge patients.

Figure 1: Secondary outcomes of the GOLIATH trial and the GOLIATH UK-specific sub-analysis comparing the GreenLight XPS[™] system with transurethral resection of the prostate for the treatment of benign prostatic hyperplasia.

A) duration of catheterisation following surgery;B) time to stable health; and C) duration of hospitalisation.

GL XPS: GreenLight XPS[™] system; TURP: transurethral resection of the prostate; TWOC: trial without catheter.

Therefore, the population of men seen in the study represent an average patient seen in clinical practice. It was not believed to be ethical to subject men with an increased risk of bleeding to randomisation between GreenLight XPS and TURP.

Further studies assessing high-risk patients previously excluded from the GOLIATH study treated with or without anticoagulants/ antiaggregants, or those with large prostate volumes, demonstrated comparable outcomes for patients receiving GreenLight or TURP in terms of flow rate, IPSS, and residual urine but with very low rates of bleeding or other complications; thus supporting the case for day-case surgery with GreenLight,^{13,14} Similar outcomes were observed when comparing efficacy and safety of bipolar TURP and PVP, with significantly shorter recovery time for PVP, again suggesting PVP is more suited for day-case surgery than bipolar TURP.¹⁵

As with any other treatment, short-stay management requires careful consideration of individual patient background and needs; however, GreenLight XPS represents a suitable treatment option for day-case surgery, high-risk, and elderly patients for whom TURP may represent a potentially unacceptably morbid procedure.

ASSESSMENT OF GREENLIGHT COST-EFFECTIVENESS

In light of recent economic challenges, there has been a global requirement for healthcare services to minimise costs. As the economic crisis continues to have an impact, both public and total healthcare spending across OECD countries have fallen sharply since 2009;⁴ a trend that has been reported around the globe.¹⁶ In many regions, this drop has been primarily driven by a collapse in the growth of government health spending; whereas in some countries, such as the UK, a level health spending or a slight increase in health spending may translate into real-time reduced funding as a result of health-service inflation.¹⁷ Therefore, it is vital for health-service economies to minimise costs in the acute hospital setting by maximising the use of day-case surgery and short-stay surgery with enhanced recovery.

In the UK, the British Association of Day Surgery (BADS) has collaborated with commissioning bodies to incentivise the move of procedures into the day-surgery arena, which has resulted in 70–75% of elective surgery being performed as day cases.

However, this trend still needs to be established cost point of view when treatments are performed in the field of urology. Newer technologies, such as inpatient procedures. However, when estimated as GreenLight XPS, allow hospitals to shift a on a day-case basis, the GreenLight system is large number of patients from 2-3 day inpatient significantly more cost-effective than TURP based procedures to an outpatient procedure thus on a 25% reduction in procedural cost, overall increasing potential savings from overnight stays lower indirect costs to treat complications and and relieving pressure on the small number of beds reoperate, and lower financial burden as a result available throughout UK hospitals. Furthermore, of efficacy and adverse-event outcomes. These values could be further improved upon with scheduling patients as day cases supports completion of procedures, as patients are not likely increasing rates of day-case surgery,²⁰ a practice that is incentivised in the UK healthcare service. to experience treatment delays as a consequence of discharge prior to surgery owing to shortage IMPLICATIONS ON CLINICAL PRACTICE of beds.

Current regulations in some European countries do not mandate early discharge of patients after Monopolar TURP has long been seen as the surgery which may lead to resistance against treatment standard for men with lower urinary tract short-stay management by clinicians and to symptoms secondary to prostatic enlargement. unnecessarily extended hospitalisation, as the Newer treatment choices, which are as effective procedure itself and patient management is very as TURP in reducing patients' symptoms, can labour-intensive. However, practice set-up and now be offered. TURP and GreenLight form part economic incentives allow UK-based clinicians of a treatment offering that can be tailored to a to discharge patients within 1 day of surgery if patient's individual circumstances and choices. deemed safe. Men should be offered the opportunity of treatment on a day-case basis with therapies It has recently been shown that although the such as GreenLight XPS, which can reduce risks of complications.

mean duration of hospitalisation was statistically lower with PVP compared with TURP (1.2 versus 4.9 days, respectively; p<0.001), rates of In the past, communication between physicians short-term complications and reinterventions and patients has lacked adequate disclosure of were comparable.¹⁸ Sensitivity analyses estimated the effects of treatment on everyday life such as savings of approximately €400 (£305) cost chance of dry orgasm or sexual dysfunction. As per procedure in favour of PVP when taking needs differ between older and younger, or lowinto account cost of equipment, consumables, risk and high-risk patients, an in-depth conversation anaesthesia, medications, inpatient hospitalisation, on the meaning of quality of life post-procedure and cost to treat complications,19 despite the is vital in choosing an adequate treatment option; shorter operating time with TURP (mean of particularly in patients who are concerned with 10 minutes). GOLIATH results resonate with certain aspects of sexual health. clinician experience in that most patients can be discharged shortly after GreenLight treatment GreenLight is effective in both symptomatic and without the need for catheterisation, compared elderly high-risk patients on anticoagulants or with patients treated with TURP, which reduced antiaggregants, and although elderly patients the risk of urethral infections and hospitalmay not be treated as day cases, GreenLight related complications. allows treatment without withdrawal of their medication.²²⁻²⁶ Furthermore, although In our experience, the GreenLight XPS system has many clinicians would limit vaporisation to been widely used to treat men with comorbidities; prostates less than 80-100 g, experience has despite this, up to 70% of patients recovered to shown that any prostate size can safely be treated an acceptable level for discharge the morning with GreenLight,27,28

In our experience, the GreenLight XPS system has been widely used to treat men with comorbidities; despite this, up to 70% of patients recovered to an acceptable level for discharge the morning after surgery,²⁰ and although the direct cost of the GreenLight system is slightly higher compared with the cost of TURP, cost-effectiveness studies have demonstrated that a discharge rate of 32% establishes GreenLight as economically viable.²¹ There are no advantages with GreenLight from a

IMPLICATIONS ON CLINICAL PRACTICE AND GUIDELINES

reinforcing patient and carer confidence through reaffirmation of the procedure by the preoperative assessment team, ambulatory care nurses, the surgeon, anaesthetist, and postoperative teams.

CONCLUSIONS

GreenLight XPS provides equivalent clinical outcomes with fewer adverse events and shorter

recovery time in a more cost-effective manner compared with TURP. The application of this new technology is suitable for the management of patients at high surgical risk. Maximal control of intra and postoperative bleeding and management of BPH surgery as a day-case is required.

24. Ruszat R et al. Safety and effectiveness 26. Woo H et al. Outcome of GreenLight 2007;100(3):593-8; discussion 598. of photoselective vaporization of the prostate (PVP) in patients on ongoing oral anticoagulation. Eur Urol. 2007;51(4):1031-8; discussion 1038-41.

25. Sandhu JS et al. Photoselective laser vaporization prostatectomy in men receiving anticoagulants. J Endourol. 2005;19(10):1196-8.

HPS 120-W Laser Therapy in Specific Patient Populations: Those in Retention, on Anticoagulants, and with Large Prostates (≥80 ml). Eur Urol. 2008;7(4):378-83. vaporization of the prostate with the potassium-titanyl-phosphate laser in men with prostates of >100 mL. BJU Int.

Click below to view the following videos:

GreenLight XPS[™] Laser Therapy System: A True Day Case Procedure

Acknowledgements

Writing assistance was provided by Dr Juliane Moloney, ApotheCom.

REFERENCES

1. Roehrborn CG. Benign prostatic laser vaporization and transurethral hyperplasia: An overview. Rev Urol. 2005;7(Suppl 9):S3-S14.

2. Tubaro A, de Nunzio C. Evolving techniques for surgical treatment of benign prostatic hyperplasia. EMJ Urol. 2015;3(2):119-22.

early outcome of transurethral resection of the prostate: A prospective multicenter evaluation of 10,654 patients. J Urol. 2008;180(1):246-9.

and Development - OECD, OECD Health spending continues to stagnate, says OECD. 2013. Available at: http://infooecd.blogspot.co.uk/2013/06/health- 12. Thomas JA. Functional results of spending-continues-to-stagnate.html. a prospective randomized controlled Last accessed: 8 July 2016.

5. Bachmann A et al. Laser prostatectomy of lower urinary tract symptoms due to benign prostate enlargement: A critical review of evidence. Curr Opin Urol. 2012; 22(1):22-33.

6. Kacker R, Williams SB. Endourologic procedures for benign prostatic hyperplasia: Review of indications and outcomes. Urol J. 2011;8(3):171-6.

7. British Association of Day Surgery BA of DS. BADS Directory of Procedures, 2011. Available at: https://www.aagbi. org/sites/default/files/Day%20Case%20 for%20web.pdf. Last accessed: 9 August 2016.

8. Bachmann A et al. 180-W XPS GreenLight laser vaporisation versus transurethral resection of the prostate for the treatment of benign prostatic 15. Thomas JA et al. Photoselective obstruction: 6-month safety and efficacy Urol. 2014:65(5):931-42.

9. Bachmann A et al. A European multicenter randomized noninferiority 16. Organisation for Economic Co- vaporization of the prostate in 66 high trial comparing 180 W GreenLight XPS operation and Development - OECD. risk patients. J Urol. 2005;173(1):158-60.

resection of the prostate for the treatment of benign prostatic obstruction: 12-month results of the GOLIATH study. J Urol. 2015;193(2):570-8.

10. Thomas JA et al. MP34-12 Functional results of a prospective randomized 3. Reich O et al. Morbidity, mortality and controlled study comparing GreenLight XPS to TURP demonstrate durable efficacy and safety at 24-months (GOLIATH): UK analysis. J Endourol. 2015;29(Suppl 1):A258.

> versus transurethral resection: Early results of a randomized trial. J Endourol. 2006;20(8):580-5.

study comparing GreenLight XPS to turp demonstrate durable efficacy and safety at 24-months (GOLIATH): UK analysis. Poster: 112485. World Congress of Endourology, London, UK, 1-4 October 2015.

13. Bachmann A et al. 180-W XPS GreenLight laser therapy for benign prostate hyperplasia: early safety, efficacy, and perioperative outcome after 201 procedures. Eur Urol. 2012;61(3): 600-7.

14. Eure GR et al. MP34-14 Photoselective vaporization of the prostate in men with large glands and in high risk men using the 180-W GreenLight XPS laser system: Results from a large multicenter retrospective study. J Endourol. 2015; 29(Suppl 1):A259.

vaporization of the prostate by 180results of a European multicentre W GreenLight laser versus bipolar randomised trial--the GOLIATH study. Eur transurethral resection of the prostate: A subset analysis of the GOLIATH trial. J Urol. 2016;195(4):e513.

OECD Health Statistics 2016. 2016. Available at: http://www.oecd.org/els/ health-systems/health-data.htm. Last accessed: 9 August 2016.

17. Nuffield Trust. A decade of austerity? - The funding pressures facing the NHS from 2010/11 to 2021/22. 2012. Available at: http://www.nuffieldtrust.org.uk/sites/ files/nuffield/121203_a_decade_of_ austerity_full_report.pdf. Last accessed: 9 August 2016.

18. Liatsikos E et al. Photoselective 4. Organisation for Economic Co-operation 11. Bouchier-Hayes DM et al. KTP laser GreenLight[™] laser vaporization versus transurethral resection of the prostate in Greece: A comparative cost analysis. J Endourol. 2012:26(2):168-73.

> 19. Canadian Agency for Drugs and Technologies in Health - CADTH. GreenLight laser for the treatment of benign prostatic hypertrophy: A review of clinical and cost-effectiveness, and safety. 2013. Available at: https://www. cadth.ca/greenlight-laser-treatmentbenign-prostatic-hypertrophy-reviewclinical-and-cost-effectiveness-and. Last accessed: 9 August 2016.

> 20. Thomas JA et al. Cost effectiveness of XPS vs TURP, a UK analysis. Eur Urol Suppl. 2014;13:e129.

> 21. Thomas JA et al. The continuing story of the cost-effectiveness of photoselective vaporization of the prostate versus transuretheral resection of the prostate for the treatment of symptomatic benign prostatic obstruction. Value Health. 2015;18(4):376-86.

> 22. Chung DE et al. Outcomes and complications after 532 nm laser prostatectomy in anticoagulated patients with benign prostatic hyperplasia. J Urol. 2011;186(3):977-81.

> 23. Reich O et al. High power (80 W) potassium-titanyl-phosphate laser

28. Skolarikos A et al. Eighteen-month results of a randomized prospective study comparing transurethral photoselective vaporization with transvesical open 27. Rajbabu K et al. Photoselective enucleation for prostatic adenomas greater than 80 cc. J Endourol. 2008; 22(10):2333-40.